Liquidia (NASDAQ:LQDA - Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $4.60 million for the quarter.
Liquidia Trading Down 0.3 %
LQDA stock traded down $0.04 during mid-day trading on Friday, reaching $14.82. The company's stock had a trading volume of 866,719 shares, compared to its average volume of 874,654. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -9.09 and a beta of 0.07. The business's 50 day moving average price is $14.30 and its 200 day moving average price is $11.84. Liquidia has a 12 month low of $8.26 and a 12 month high of $16.99.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on LQDA shares. Wells Fargo & Company started coverage on Liquidia in a report on Friday, December 20th. They issued an "overweight" rating and a $20.00 target price for the company. HC Wainwright restated a "buy" rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Finally, Needham & Company LLC restated a "buy" rating and set a $19.00 price objective on shares of Liquidia in a report on Thursday, January 9th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Liquidia presently has a consensus rating of "Buy" and an average price target of $25.38.
Get Our Latest Research Report on Liquidia
Insiders Place Their Bets
In other news, insider Rajeev Saggar sold 6,249 shares of the company's stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $73,613.22. Following the transaction, the insider now owns 270,388 shares of the company's stock, valued at $3,185,170.64. This represents a 2.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Roger Jeffs sold 22,343 shares of the business's stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the sale, the chief executive officer now owns 1,019,177 shares in the company, valued at approximately $12,005,905.06. The trade was a 2.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,245 shares of company stock valued at $843,326. Insiders own 30.10% of the company's stock.
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Further Reading
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
